NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today ...
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society ...
StockStory.org on MSN
NeoGenomics (NASDAQ:NEO) Misses Q2 Sales Targets, Stock Drops 15.8%
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year revenue guidance of $723 million at the ...
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the PanTracer™ LBx test has received coverage from the Centers for ...
NeoGenomics (NEO) moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a ...
FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Tuesday reported a loss of $9.9 million in its fourth quarter. The Fort Myers, Florida-based company said it had a loss of 8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results